Сравнение

Eloralintide vs. VK2735

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Метаболизм

Номер CAS

нет данных

Молекулярная масса

нет данных

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Eloralintide

Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Eloralintide	VK2735
Германия	Не одобрено	Не одобрено
США	Не одобрено	Не одобрено

Полные записи

Frequently asked questions

What is the difference between Eloralintide and VK2735?: Eloralintide is classified as "Метаболизм", while VK2735 is classified as "Метаболизм". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Eloralintide or VK2735?: The highest available evidence level is "РКИ на людях" for Eloralintide and "РКИ на людях" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Eloralintide and VK2735 in Germany and the United States?: Германия: Eloralintide — Не одобрено, VK2735 — Не одобрено. США: Eloralintide — Не одобрено, VK2735 — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

Eloralintide

VK2735

Германия

Не одобрено

США

Не одобрено

Frequently asked questions

What is the difference between Eloralintide and VK2735?

Eloralintide is classified as "Метаболизм", while VK2735 is classified as "Метаболизм". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Eloralintide or VK2735?

The highest available evidence level is "РКИ на людях" for Eloralintide and "РКИ на людях" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Eloralintide and VK2735 in Germany and the United States?

Германия: Eloralintide — Не одобрено, VK2735 — Не одобрено. США: Eloralintide — Не одобрено, VK2735 — Не одобрено. These are factual summaries with source and review date on the individual pages.